AI Engines For more Details: Perplexity Kagi Labs You
Glaucoma Treatment: Carteolol hydrochloride is a beta-blocker eye drop medication that works by reducing the production of aqueous humor, the fluid that fills the front part of the eye. By decreasing the production of this fluid, carteolol helps lower intraocular pressure (IOP), which is essential for managing glaucoma and preventing optic nerve damage.
Ocular Hypertension Management: Ocular hypertension refers to elevated intraocular pressure without optic nerve damage or vision loss. Carteolol hydrochloride can be used to lower IOP in individuals with ocular hypertension to reduce the risk of developing glaucoma.
Open-Angle Glaucoma: Carteolol hydrochloride is particularly effective in treating open-angle glaucoma, the most common form of glaucoma characterized by a gradual increase in IOP over time.
Normal-Tension Glaucoma: In some cases of normal-tension glaucoma, where optic nerve damage and visual field loss occur despite normal intraocular pressure, carteolol hydrochloride may still be prescribed to help lower IOP and potentially slow down disease progression.
Reduction of Intraocular Pressure: By reducing intraocular pressure, carteolol hydrochloride helps relieve symptoms associated with elevated IOP, such as eye pain, redness, blurred vision, and visual disturbances.
Prevention of Optic Nerve Damage: By lowering intraocular pressure, carteolol hydrochloride helps protect the optic nerve from damage caused by increased pressure within the eye. This can help prevent vision loss and preserve visual function in individuals with glaucoma.
Preservation of Visual Field: By controlling intraocular pressure, carteolol hydrochloride may help preserve the visual field, which is essential for maintaining functional vision in individuals with glaucoma.
Long-Term Management: Carteolol hydrochloride is often used as a long-term treatment to manage glaucoma and ocular hypertension. Regular use of the medication as prescribed by an ophthalmologist is important for maintaining optimal intraocular pressure control and preventing disease progression.
Combination Therapy: In some cases, carteolol hydrochloride may be used in combination with other classes of glaucoma medications, such as prostaglandin analogs or carbonic anhydrase inhibitors, to achieve better intraocular pressure control.
Side Effects and Precautions: Like all medications, carteolol hydrochloride may cause side effects such as eye irritation, burning, stinging, blurred vision, and systemic side effects if absorbed into the bloodstream. It is important for patients to follow their healthcare provider's instructions for proper administration and to report any adverse reactions.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
0 | 1 | Bacteroides sp. A1C1 | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
0 | 1 | Bacteroides sp. CACC 737 | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
0 | 1 | Eggerthella guodeyinii | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
0 | 1 | Bacteroides humanifaecis | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
0 | 1 | Bacteroides sp. HF-162 | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Bacteroides sp. D2 | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Bifidobacterium breve | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
0 | 1 | Bacteroides sp. M10 | species | Decreases |
0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Veillonella rodentium | species | Decreases |
0 | 1 | Actinomyces naeslundii | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
0 | 1 | Olsenella sp. oral taxon 807 | species | Decreases |
0 | 1 | Bacteroides caecimuris | species | Decreases |
0 | 1 | Bacteroides helcogenes | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Amedibacterium intestinale | species | Decreases |
0 | 1 | Bifidobacterium angulatum | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
Acne | 0.2 | -0.2 | |
ADHD | 2.8 | 0.4 | 6 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.2 | 0.5 |
Allergic Rhinitis (Hay Fever) | 1.3 | 2 | -0.54 |
Allergies | 4 | 2.5 | 0.6 |
Allergy to milk products | 1.7 | 0.9 | 0.89 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 4.1 | 2.5 | 0.64 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 1.3 | 0.38 |
Ankylosing spondylitis | 2.4 | 0.5 | 3.8 |
Anorexia Nervosa | 0.9 | 0.9 | 0 |
Antiphospholipid syndrome (APS) | 0.6 | 0.1 | 5 |
Asthma | 2.8 | 1.9 | 0.47 |
Atherosclerosis | 1.2 | 0.6 | 1 |
Atrial fibrillation | 1.4 | 1.1 | 0.27 |
Autism | 4.8 | 4.5 | 0.07 |
Autoimmune Disease | 0.6 | 0.4 | 0.5 |
Barrett esophagus cancer | 0.2 | 0.1 | 1 |
benign prostatic hyperplasia | 0.4 | 0.2 | 1 |
Biofilm | 1 | 1 | |
Bipolar Disorder | 1.7 | 0.9 | 0.89 |
Brain Trauma | 0.3 | 0.7 | -1.33 |
Breast Cancer | 0.5 | 0.5 | |
Cancer (General) | 0.2 | 1.6 | -7 |
Carcinoma | 2.1 | 1.1 | 0.91 |
Celiac Disease | 1.2 | 2.1 | -0.75 |
Cerebral Palsy | 1.1 | 0.6 | 0.83 |
Chronic Fatigue Syndrome | 4.3 | 2.7 | 0.59 |
Chronic Kidney Disease | 2.7 | 0.6 | 3.5 |
Chronic Lyme | 0.5 | 0.3 | 0.67 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.4 | 1.75 |
Chronic Urticaria (Hives) | 1 | 0.6 | 0.67 |
Coagulation / Micro clot triggering bacteria | 1.1 | 0.4 | 1.75 |
Cognitive Function | 1.2 | 0.5 | 1.4 |
Colorectal Cancer | 3.3 | 1.1 | 2 |
Constipation | 0.9 | 0.1 | 8 |
Coronary artery disease | 1.2 | 0.5 | 1.4 |
COVID-19 | 7 | 5.8 | 0.21 |
Crohn's Disease | 4.6 | 2.3 | 1 |
Cushing's Syndrome (hypercortisolism) | 0.2 | -0.2 | |
cystic fibrosis | 0.7 | 0.8 | -0.14 |
d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
deep vein thrombosis | 1.2 | 0.7 | 0.71 |
Denture Wearers Oral Shifts | 0.6 | 0.6 | |
Depression | 6.6 | 4.6 | 0.43 |
Dermatomyositis | 0.1 | 0.2 | -1 |
Eczema | 0.8 | 0.9 | -0.13 |
Endometriosis | 1.8 | 0.9 | 1 |
Eosinophilic Esophagitis | 0 | 0.2 | 0 |
Epilepsy | 2 | 2.2 | -0.1 |
erectile dysfunction | 0.8 | 0.2 | 3 |
Fibromyalgia | 2.1 | 1.2 | 0.75 |
Functional constipation / chronic idiopathic constipation | 3 | 1.7 | 0.76 |
gallstone disease (gsd) | 1.7 | 0.6 | 1.83 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.1 | 1 |
Generalized anxiety disorder | 1.9 | 1.4 | 0.36 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 2.1 | 0.6 | 2.5 |
Graves' disease | 1 | 1.2 | -0.2 |
Gulf War Syndrome | 0.3 | 1.2 | -3 |
Halitosis | 0.6 | 0.1 | 5 |
Hashimoto's thyroiditis | 1.5 | 0.9 | 0.67 |
Heart Failure | 2.4 | 0.9 | 1.67 |
hemorrhagic stroke | 0.5 | 0.5 | |
Hidradenitis Suppurativa | 0.5 | 0.1 | 4 |
High Histamine/low DAO | 1 | 0.4 | 1.5 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
hyperglycemia | 1.4 | 1.6 | -0.14 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 3.2 | 2.2 | 0.45 |
Hypothyroidism | 0.4 | 0.6 | -0.5 |
Hypoxia | 1.6 | 1.6 | |
IgA nephropathy (IgAN) | 1.3 | 2.1 | -0.62 |
Inflammatory Bowel Disease | 5.5 | 4.3 | 0.28 |
Insomnia | 0.8 | 1.9 | -1.37 |
Intelligence | 1.5 | 1.5 | |
Intracranial aneurysms | 0.7 | 0 | 0 |
Irritable Bowel Syndrome | 4.1 | 3.6 | 0.14 |
ischemic stroke | 2 | 0.7 | 1.86 |
Liver Cirrhosis | 3.7 | 3 | 0.23 |
Long COVID | 2.8 | 3 | -0.07 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 1 | 1.1 | -0.1 |
Lymphoma | 0.4 | 0.4 | |
Mast Cell Issues / mastitis | 0.5 | 0.4 | 0.25 |
ME/CFS with IBS | 0.3 | 0.9 | -2 |
ME/CFS without IBS | 1.3 | 1.4 | -0.08 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 1.4 | 0.4 | 2.5 |
Metabolic Syndrome | 4 | 4.3 | -0.07 |
Mood Disorders | 7 | 4.4 | 0.59 |
multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
Multiple Sclerosis | 4.8 | 2.4 | 1 |
Multiple system atrophy (MSA) | 1.4 | 0.4 | 2.5 |
myasthenia gravis | 0.5 | 0.2 | 1.5 |
neuropathic pain | 0.4 | 1.2 | -2 |
Neuropathy (all types) | 0.9 | 0.6 | 0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.7 | 2.4 | 0.13 |
NonCeliac Gluten Sensitivity | 1.4 | 0.4 | 2.5 |
Obesity | 5.1 | 3.7 | 0.38 |
obsessive-compulsive disorder | 3.7 | 1.4 | 1.64 |
Osteoarthritis | 1.6 | 1.1 | 0.45 |
Osteoporosis | 1.6 | 1.3 | 0.23 |
pancreatic cancer | 0.2 | 0.1 | 1 |
Parkinson's Disease | 4.7 | 1.9 | 1.47 |
Polycystic ovary syndrome | 3.1 | 1.9 | 0.63 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.2 | -1 |
Premenstrual dysphoric disorder | 0.2 | 0.2 | 0 |
primary biliary cholangitis | 0.5 | 1 | -1 |
Primary sclerosing cholangitis | 1.4 | 1 | 0.4 |
Psoriasis | 2.1 | 1.5 | 0.4 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 1.1 | 2.64 |
Rosacea | 0.5 | 0.2 | 1.5 |
Schizophrenia | 4.3 | 1.6 | 1.69 |
scoliosis | 0.4 | 0.4 | 0 |
Sjögren syndrome | 1.1 | 1.8 | -0.64 |
Sleep Apnea | 0.8 | 0.7 | 0.14 |
Slow gastric motility / Gastroparesis | 1 | 0.2 | 4 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.4 | 1.75 |
Stress / posttraumatic stress disorder | 2.1 | 1.9 | 0.11 |
Systemic Lupus Erythematosus | 1.8 | 0.6 | 2 |
Tic Disorder | 0.4 | 0.4 | 0 |
Tourette syndrome | 0.7 | 0.2 | 2.5 |
Type 1 Diabetes | 2.5 | 1.8 | 0.39 |
Type 2 Diabetes | 3.6 | 4.1 | -0.14 |
Ulcerative colitis | 2.6 | 4.2 | -0.62 |
Unhealthy Ageing | 1.9 | 0.9 | 1.11 |
Vitiligo | 1 | 0.9 | 0.11 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]